Corvus Pharmaceuticals Inc (NASDAQ:CRVS) CEO Richard A. Md Miller acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The stock was purchased at an average price of $8.50 per share, with a total value of $850,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) opened at $10.63 on Wednesday. The firm has a market capitalization of $221.40 and a PE ratio of -3.91. Corvus Pharmaceuticals Inc has a fifty-two week low of $7.42 and a fifty-two week high of $22.14.
Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Thursday, March 1st. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.18. equities analysts forecast that Corvus Pharmaceuticals Inc will post -3.15 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP bought a new position in Corvus Pharmaceuticals in the second quarter worth about $320,000. Vanguard Group Inc. raised its holdings in Corvus Pharmaceuticals by 37.1% in the second quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock worth $4,520,000 after purchasing an additional 101,013 shares in the last quarter. Northern Trust Corp raised its holdings in Corvus Pharmaceuticals by 97.6% in the second quarter. Northern Trust Corp now owns 86,525 shares of the company’s stock worth $1,047,000 after purchasing an additional 42,739 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in Corvus Pharmaceuticals by 225.2% in the second quarter. TIAA CREF Investment Management LLC now owns 23,354 shares of the company’s stock worth $283,000 after purchasing an additional 16,173 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Corvus Pharmaceuticals in the fourth quarter worth about $150,000. Institutional investors and hedge funds own 82.71% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Insider Buying: Corvus Pharmaceuticals Inc (CRVS) CEO Acquires 100,000 Shares of Stock” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://sportsperspectives.com/2018/03/14/insider-buying-corvus-pharmaceuticals-inc-crvs-ceo-acquires-100000-shares-of-stock.html.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.